Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 316

1.

Viral Therapy for Bladder Cancer: Everything Old is New Again.

Gomella LG.

Can J Urol. 2019 Aug;26(4):9802. No abstract available.

2.

Prostate Contrast Enhanced Transrectal Ultrasound Evaluation of the Prostate With Whole-Mount Prostatectomy Correlation.

Trabulsi EJ, Calio BP, Kamel SI, Gomella LG, Forsberg F, McCue P, Halpern EJ.

Urology. 2019 Aug 1. pii: S0090-4295(19)30696-X. doi: 10.1016/j.urology.2019.07.026. [Epub ahead of print]

PMID:
31377256
3.

Prevalence of Suspected Hereditary Cancer Syndromes and Germline Mutations Among a Diverse Cohort of Probands Reporting a Family History of Prostate Cancer: Toward Informing Cascade Testing for Men.

Chandrasekar T, Gross L, Gomella LG, Hegarty SE, Leong JY, Giri VN.

Eur Urol Oncol. 2019 Jul 2. pii: S2588-9311(19)30085-9. doi: 10.1016/j.euo.2019.06.010. [Epub ahead of print]

PMID:
31278035
4.

Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies.

Dylgjeri E, McNair C, Goodwin JF, Raymon HK, McCue PA, Shafi AA, Leiby BE, de Leeuw R, Kothari V, McCann JJ, Mandigo AC, Chand SN, Schiewer MJ, Brand LJ, Vasilevskaya I, Gordon N, Laufer TS, Gomella LG, Lallas CD, Trabulsi EJ, Feng FY, Filvaroff EH, Hege K, Rathkopf D, Knudsen KE.

Clin Cancer Res. 2019 Sep 15;25(18):5623-5637. doi: 10.1158/1078-0432.CCR-18-2207. Epub 2019 Jul 2.

PMID:
31266833
5.

Evolution of the Liquid Biopsy in Metastatic Prostate Cancer.

Moreno JG, Gomella LG.

Urology. 2019 Jun 14. pii: S0090-4295(19)30535-7. doi: 10.1016/j.urology.2019.06.006. [Epub ahead of print] Review.

PMID:
31207303
6.

Impact of Tumor Regional Involvement on Active Surveillance Outcomes: Validation of the Cumulative Cancer Location Metric in a US Population.

Leong JY, Capella C, Teplitsky S, Gomella LG, Trabulsi EJ, Lallas CD, Chandrasekar T.

Eur Urol Focus. 2019 May 18. pii: S2405-4569(19)30136-1. doi: 10.1016/j.euf.2019.05.001. [Epub ahead of print]

PMID:
31109856
7.

Overlapping surgeries: defining the 'critical portions' of the procedure.

Leong JY, Calio B, Shah M, Sullivan P, Trabulsi EJ, Gomella LG, Lallas CD.

Can J Urol. 2019 Apr;26(2):9694-9698.

8.

Is BCG a Hazardous Drug? Ask NIOSH, OSHA, and the USP.

Gomella LG.

Can J Urol. 2019 Apr;26(2):9687-9689. No abstract available.

9.

Germline Testing for Men With Prostate Cancer: Navigating an Expanding New World of Genetic Evaluation for Precision Therapy and Precision Management.

Giri VN, Hyatt C, Gomella LG.

J Clin Oncol. 2019 Jun 10;37(17):1455-1459. doi: 10.1200/JCO.18.02181. Epub 2019 Apr 12. No abstract available.

PMID:
30978156
10.

Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial.

Rosenthal SA, Hu C, Sartor O, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Horwitz EM, Raben A, Peters CA, Feng FY, Shipley WU, Sandler HM.

J Clin Oncol. 2019 May 10;37(14):1159-1168. doi: 10.1200/JCO.18.02158. Epub 2019 Mar 12.

PMID:
30860948
11.

Before Ordering a Genetic Test Get to Know GINA.

Gomella LG.

Can J Urol. 2018 Dec;25(6):9569. No abstract available.

12.

Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response.

Shafi AA, Schiewer MJ, de Leeuw R, Dylgjeri E, McCue PA, Shah N, Gomella LG, Lallas CD, Trabulsi EJ, Centenera MM, Hickey TE, Butler LM, Raj G, Tilley WD, Cukierman E, Knudsen KE.

Eur Urol Oncol. 2018 Sep;1(4):325-337. doi: 10.1016/j.euo.2018.04.019. Epub 2018 Jun 6.

13.

PARP-1 regulates DNA repair factor availability.

Schiewer MJ, Mandigo AC, Gordon N, Huang F, Gaur S, de Leeuw R, Zhao SG, Evans J, Han S, Parsons T, Birbe R, McCue P, McNair C, Chand SN, Cendon-Florez Y, Gallagher P, McCann JJ, Poudel Neupane N, Shafi AA, Dylgjeri E, Brand LJ, Visakorpi T, Raj GV, Lallas CD, Trabulsi EJ, Gomella LG, Dicker AP, Kelly WK, Leiby BE, Knudsen B, Feng FY, Knudsen KE.

EMBO Mol Med. 2018 Dec;10(12). pii: e8816. doi: 10.15252/emmm.201708816.

14.

Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.

Giri VN, Hegarty SE, Hyatt C, O'Leary E, Garcia J, Knudsen KE, Kelly WK, Gomella LG.

Prostate. 2019 Mar;79(4):333-339. doi: 10.1002/pros.23739. Epub 2018 Nov 18.

PMID:
30450585
15.

Should Urology Reconsider the Routine Use of Fluoroquinolones?

Gomella LG.

Can J Urol. 2018 Aug;25(4):9366. No abstract available.

16.

A patient-derived explant (PDE) model of hormone-dependent cancer.

Centenera MM, Hickey TE, Jindal S, Ryan NK, Ravindranathan P, Mohammed H, Robinson JL, Schiewer MJ, Ma S, Kapur P, Sutherland PD, Hoffmann CE, Roehrborn CG, Gomella LG, Carroll JS, Birrell SN, Knudsen KE, Raj GV, Butler LM, Tilley WD.

Mol Oncol. 2018 Sep;12(9):1608-1622. doi: 10.1002/1878-0261.12354. Epub 2018 Aug 16.

17.

A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III).

Crawford ED, Koo PJ, Shore N, Slovin SF, Concepcion RS, Freedland SJ, Gomella LG, Karsh L, Keane TE, Maroni P, Penson D, Petrylak DP, Ross A, Mouraviev V, Reiter RE, Divgi C, Yu EY; RADAR III Group.

J Urol. 2019 Apr;201(4):682-692. doi: 10.1016/j.juro.2018.05.164. Review.

PMID:
30077557
18.

Prostate Cancer CRPC Stage M0 and M1: Do We Need Stage M0.5?

Gomella LG.

Can J Urol. 2018 Apr;25(2):9220. No abstract available.

19.

Multidisciplinary Clinical Treatment of Head and Neck Cancer.

Mark JR, Kelly WK, Gomella LG.

JAMA Otolaryngol Head Neck Surg. 2018 May 1;144(5):460-461. doi: 10.1001/jamaoto.2017.3437. No abstract available.

PMID:
29543958
20.

VPAC1-targeted PET/CT scan: improved molecular imaging for the diagnosis of prostate cancer using a novel cell surface antigen.

Truong H, Gomella LG, Thakur ML, Trabulsi EJ.

World J Urol. 2018 May;36(5):719-726. doi: 10.1007/s00345-018-2263-1. Epub 2018 Mar 14. Review.

21.

New Urologic Oncology Drugs and The New Toxicities.

Gomella LG.

Can J Urol. 2017 Dec;24(6):9075. No abstract available.

22.

Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG.

J Clin Oncol. 2018 Feb 1;36(4):414-424. doi: 10.1200/JCO.2017.74.1173. Epub 2017 Dec 13. Review.

23.

Where have all the sperm gone?

Gomella LG.

Can J Urol. 2017 Oct;24(5):8972. No abstract available.

24.

Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.

Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, Gomella LG, Kamat AM, Lotan Y, Svatek RS, Bivalacqua TJ, Grubb RL 3rd, Krupski TL, Lerner SP, Woods ME, Inman BA, Milowsky MI, Boyd A, Treasure FP, Gregory G, Sawutz DG, Yla-Herttuala S, Parker NR, Dinney CPN.

J Clin Oncol. 2017 Oct 20;35(30):3410-3416. doi: 10.1200/JCO.2017.72.3064. Epub 2017 Aug 23. Erratum in: J Clin Oncol. 2019 Aug 20;37(24):2187.

25.

The Urology Guide to Coffee and Tea.

Gomella LG.

Can J Urol. 2017 Jun;24(3):8782-8783. No abstract available.

26.

Nonpalpable Intratesticular Mass in a Young Man With a History of Contralateral Retractile Testis.

Mark JR, Gomella LG.

Oncology (Williston Park). 2017 Jun 15;31(6):484, 489-91. No abstract available.

27.

The Liquid Biopsy for Prostate Cancer 25 Years Later.

Gomella LG.

Can J Urol. 2017 Apr;24(2):8693-8694. No abstract available.

28.

The perlecan-interacting growth factor progranulin regulates ubiquitination, sorting, and lysosomal degradation of sortilin.

Tanimoto R, Palladino C, Xu SQ, Buraschi S, Neill T, Gomella LG, Peiper SC, Belfiore A, Iozzo RV, Morrione A.

Matrix Biol. 2017 Dec;64:27-39. doi: 10.1016/j.matbio.2017.04.001. Epub 2017 Apr 20.

PMID:
28433812
29.

The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II).

Crawford ED, Petrylak DP, Shore N, Saad F, Slovin SF, Vogelzang NJ, Keane TE, Koo PJ, Gomella LG, O'Sullivan JM, Tombal B, Concepcion RS, Sieber P, Stone NN, Finkelstein SE, Yu EY; Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence (RADAR II) Group.

Urology. 2017 Jun;104:150-159. doi: 10.1016/j.urology.2016.12.033. Epub 2017 Mar 14. Review.

PMID:
28302580
30.

Fluorescence in situ hybridization (FISH) in the diagnosis of bladder and upper tract urothelial carcinoma: the largest single-institution experience to date.

Gomella LG, Mann MJ, Cleary RC, Hubosky SG, Bagley DH, Thumar AB, McCue PA, Lallas CD, Trabulsi EJ.

Can J Urol. 2017 Feb;24(1):8620-8626.

31.

Prostate Cancer Statistics: Anything You Want Them To Be.

Gomella LG.

Can J Urol. 2017 Feb;24(1):8603-8604. No abstract available.

32.

Prevalence and Characteristics of Patients with Suspected Inherited Renal Cell Cancer: Application of the ACMG/NSGC Genetic Referral Guidelines to Patient Cohorts.

Truong H, Hegarty SE, Gomella LG, Kelly WK, Trabulsi EJ, Lallas CD, Giri VN.

J Genet Couns. 2017 Jun;26(3):548-555. doi: 10.1007/s10897-016-0020-4. Epub 2017 Jan 19.

PMID:
28101821
33.

Editorial Comment.

Gomella LG.

J Urol. 2017 Mar;197(3 Pt 1):601. doi: 10.1016/j.juro.2016.09.151. Epub 2016 Dec 16. No abstract available.

PMID:
27992742
34.

v-Src Oncogene Induces Trop2 Proteolytic Activation via Cyclin D1.

Ju X, Jiao X, Ertel A, Casimiro MC, Di Sante G, Deng S, Li Z, Di Rocco A, Zhan T, Hawkins A, Stoyanova T, Andò S, Fatatis A, Lisanti MP, Gomella LG, Languino LR, Pestell RG.

Cancer Res. 2016 Nov 15;76(22):6723-6734. doi: 10.1158/0008-5472.CAN-15-3327. Epub 2016 Sep 15.

35.

Suppression of progranulin expression inhibits bladder cancer growth and sensitizes cancer cells to cisplatin.

Buraschi S, Xu SQ, Stefanello M, Moskalev I, Morcavallo A, Genua M, Tanimoto R, Birbe R, Peiper SC, Gomella LG, Belfiore A, Black PC, Iozzo RV, Morrione A.

Oncotarget. 2016 Jun 28;7(26):39980-39995. doi: 10.18632/oncotarget.9556.

36.

Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report.

Kim H, Alshalalfa M, Hoffman-Censits J, Lallas CD, Davicioni E, Lin J, Birbe R, Erho N, Lehrer J, Ashab HA, Takhar M, Olson A, Lam LL, Kelly WK, Knudsen KE, Thangavel C, Seiler R, Feng FY, Schaeffer EM, Trabulsi EJ, Gomella LG, Hurwitz MD, Dicker AP, Den RB.

Urol Case Rep. 2016 Oct 1;9:51-54. eCollection 2016 Nov.

37.

Prostate, Breast and Ovarian Cancer Genetic Risk Assessment: Connecting the Dots.

Gomella LG.

Can J Urol. 2016 Oct;23(5):8429. No abstract available.

38.

Decipher correlation patterns post prostatectomy: initial experience from 2 342 prospective patients.

Den RB, Santiago-Jimenez M, Alter J, Schliekelman M, Wagner JR, Renzulli Ii JF, Lee DI, Brito CG, Monahan K, Gburek B, Kella N, Vallabhan G, Abdollah F, Trabulsi EJ, Lallas CD, Gomella LG, Woodlief TL, Haddad Z, Lam LL, Deheshi S, Wang Q, Choeurng V, du Plessis M, Jordan J, Parks B, Shin H, Buerki C, Yousefi K, Davicioni E, Patel VR, Shah NL.

Prostate Cancer Prostatic Dis. 2016 Dec;19(4):374-379. doi: 10.1038/pcan.2016.38. Epub 2016 Aug 30.

39.

Big Data Equals Big Challenges for Prostate Cancer.

Gomella LG.

Can J Urol. 2016 Aug;23(4):8329. No abstract available.

40.

Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study.

Myers RE, Leader AE, Censits JH, Trabulsi EJ, Keith SW, Petrich AM, Quinn AM, Den RB, Hurwitz MD, Lallas CD, Hegarty SE, Dicker AP, Zeigler-Johnson CM, Giri VN, Ayaz H, Gomella LG.

J Cancer Educ. 2018 Feb;33(1):180-185. doi: 10.1007/s13187-016-1073-7.

PMID:
27418065
41.

Dosing, administration, and safety of radium-223: How I do it.

Dan TD, Doyle L, Raval AJ, Pridjian A, Gomella LG, Den RB.

Can J Urol. 2016 Jun;23(3):8301-5.

PMID:
27347625
42.

Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk.

Ross AE, Den RB, Yousefi K, Trock BJ, Tosoian J, Davicioni E, Thompson DJ, Choeurng V, Haddad Z, Tran PT, Trabulsi EJ, Gomella LG, Lallas CD, Abdollah F, Feng FY, Klein EA, Dicker AP, Freedland SJ, Karnes RJ, Schaeffer EM.

Prostate Cancer Prostatic Dis. 2016 Sep;19(3):277-82. doi: 10.1038/pcan.2016.15. Epub 2016 May 3.

43.

How I Do It: Genetic counseling and genetic testing for inherited prostate cancer.

Giri VN, Gross L, Gomella LG, Hyatt C.

Can J Urol. 2016 Apr;23(2):8247-53. Review.

44.

TV Drug Commercials: Keeping Physicians Informed.

Gomella LG.

Can J Urol. 2016 Apr;23(2):8188. No abstract available.

45.

Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer.

Fizazi K, Chi KN, de Bono JS, Gomella LG, Miller K, Rathkopf DE, Ryan CJ, Scher HI, Shore ND, De Porre P, Londhe A, McGowan T, Pelhivanov N, Charnas R, Todd MB, Montgomery B.

Eur Urol. 2016 Sep;70(3):438-44. doi: 10.1016/j.eururo.2016.02.035. Epub 2016 Mar 7.

46.

Punishing Physicians for PSA Screening.

Gomella LG.

Can J Urol. 2015 Dec;22(6):8042. No abstract available.

47.

Robotic and Open Radical Prostatectomy: Celebrating Oncologic Equivalence.

Gomella LG.

Can J Urol. 2015 Oct;22(5):7942-3. No abstract available.

48.

DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis.

Goodwin JF, Kothari V, Drake JM, Zhao S, Dylgjeri E, Dean JL, Schiewer MJ, McNair C, Jones JK, Aytes A, Magee MS, Snook AE, Zhu Z, Den RB, Birbe RC, Gomella LG, Graham NA, Vashisht AA, Wohlschlegel JA, Graeber TG, Karnes RJ, Takhar M, Davicioni E, Tomlins SA, Abate-Shen C, Sharifi N, Witte ON, Feng FY, Knudsen KE.

Cancer Cell. 2015 Jul 13;28(1):97-113. doi: 10.1016/j.ccell.2015.06.004.

49.

Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia.

Liao Z, Gu L, Vergalli J, Mariani SA, De Dominici M, Lokareddy RK, Dagvadorj A, Purushottamachar P, McCue PA, Trabulsi E, Lallas CD, Gupta S, Ellsworth E, Blackmon S, Ertel A, Fortina P, Leiby B, Xia G, Rui H, Hoang DT, Gomella LG, Cingolani G, Njar V, Pattabiraman N, Calabretta B, Nevalainen MT.

Mol Cancer Ther. 2015 Aug;14(8):1777-93. doi: 10.1158/1535-7163.MCT-14-0883. Epub 2015 May 29.

50.

Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy.

George DJ, Nabhan C, DeVries T, Whitmore JB, Gomella LG.

Cancer Immunol Res. 2015 Sep;3(9):1063-9. doi: 10.1158/2326-6066.CIR-15-0006. Epub 2015 May 5.

Supplemental Content

Loading ...
Support Center